Oncology Division

RALEIGH, N.C.–(EMWNews)–INC Research ®,

Inc., a therapeutically-focused contract research organization (CRO)

with a process for delivering reliable results, today announced Nick

Kenny, Ph.D. as the senior vice president of Oncology. Dr. Kenny began

his career at INC Research in 2006 as senior project director Oncology.

He was quickly promoted to executive director of Oncology in 2007.

Earlier this year, he was named vice president of Oncology where he has

proven his ability to drive the overall strategy and direction for this

significant division for the CRO.

“Nick was the obvious choice to step into this

senior management role in oncology,” said John

Potthoff, COO of INC Research. “Not only does

he have impeccable therapeutic expertise, but he has been instrumental

in fine tuning the methodologies that we use today in our Trusted

Process for delivering high quality clinical results that meet or exceed

customer expectations. We are confident that Nick can continue to build

our successful oncology practice.”

Dr. Kenny has 25 years of research, development and international

project integration experience in the CRO and academic segments. Prior

to INC Research, he held various management positions at CROs where he

established the strategic direction of clinical programs, as well as

global oversight of project management, clinical monitoring and

regulatory staff. Prior to his move to industry, Dr. Kenny spent 15

years in endocrinology and cell biology research and teaching in the UK,

Canada, and the United States where he was assistant professor in the

College of Medicine at the University of Vermont. Over the past 10

years, Dr. Kenny’s drug development expertise

has been primarily focused upon oncology clinical development. He is

continually sought after as a subject matter expert to represent both

CRO and oncology perspectives by industry publications and conferences.

“I am thrilled to be working with a CRO that

is as passionate about oncology drug development as I am,”

said Kenny. “INC Research has developed an

incredible track record for global oncology trials. I intend to

reinforce that reputation by continued advancement of the quality of

service and depth of expertise the oncology practice offers to support

our customers in bringing forward new treatments for cancer patients.”

INC Research is committed to supporting new and better therapeutic

options for oncology drug treatments. The CRO has conducted more than

300 Phase I-IV oncology trials that investigated over 140 new and

various anticancer therapies. Global studies have included almost 26,000

cancer patients in more than 3,200 investigative sites.

About INC Research^®

Inc.

INC Research is a therapeutically-focused contract research organization

with a high performance reputation for conducting global clinical

development programs of the highest integrity. Pharmaceutical and

biotechnology companies look to INC Research for a complete range of

customized Phase I through Phase IV programs in therapeutic areas of

specialty, and in innovative pediatric and women’s

health trials. The company’s “The

Trusted Process^®”

methodology and therapeutic foresight leads customers to more confident,

better-informed drug and device development decisions. INC Research is

headquartered in Raleigh, North Carolina, with 25 office locations and a

presence in 32 countries worldwide. For more information please visit www.incresearch.com.

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions